Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Supports biomarker use in CV smoking assessment; leaves open prospective validation of counseling protocols.
Smoking is a significant risk factor for all aspects of cardiovascular disease. It affects the myocardium and occludes the blood supply, increases atherosclerosis and contributes to myocardial infarction, cardiomyopathy and peripheral vascular disease. Nicotine, carbon monoxide and other tobacco constituents have direct effects on the endothelium, causing inflammation, atheroma and thrombosis. Free radicals are abundant in cigarette smoke and these initiate and intensify the inflammatory cascade, increasing leukocyte infiltration and cytokine production. It is important to obtain accurate information about smoking habit, but data gathering should not rely on self-report which is misleading, but should use some form of biochemical biomarker, preferably cotinine. Smokers should then be intensively counselled, both by in-house trained staff and via the specialist smoking cessation services. It should be explained to patients in basic terms about the deleterious effects of smoking on heart disease and atherosclerosis. Patients should be encouraged to use all sources of counselling and to visit their pharmacist to obtain advice about the best way to use nicotine replacement therapies or other pharmaceutical aids to quit.
No takes yet. Share an insight, caveat, or question.
C. T. Graham (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: